TY - JOUR
T1 - Biomimetic cellular vectors for enhancing drug delivery to the lungs
AU - Evangelopoulos, Michael
AU - Yazdi, Iman K.
AU - Acciardo, Stefania
AU - Palomba, Roberto
AU - Giordano, Federica
AU - Pasto, Anna
AU - Sushnitha, Manuela
AU - Martinez, Jonathan O.
AU - Basu, Nupur
AU - Torres, Armando
AU - Hmaidan, Sarah
AU - Parodi, Alessandro
AU - Tasciotti, Ennio
N1 - Funding Information:
This work was funded by the Cancer Prevention & Research Institute of Texas (grant number RP170466), NCI and the Office of Research on Women’s Health (grant number 1R56CA213859-01A1), and The Cullen Trust for Health Care (grant number 18130014). The authors would like to thank Shilpa Scaria and Kelly A. Hartman for technical assistance, Jianhua “James” Gu and the HMRI Scanning Electron Microscope and Atomic Force Microscope Core Facility for electron microscopy services, Kemi Cui and the HMRI Advanced Cellular and Tissue Microscope Core Facility for traditional confocal scanning services, David Haviland and the HMRI Flow Cytometry Core Facility for flow cytometry setup and acquisition, the HMRI Intravital Microscopy Core facility and Matthew G. Landry for excellent graphical support.
Publisher Copyright:
© 2020, The Author(s).
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Despite recent advances in drug delivery, the targeted treatment of unhealthy cells or tissues continues to remain a priority. In cancer (much like other pathologies), delivery vectors are designed to exploit physical and biological features of unhealthy tissues that are not always homogenous across the disease. In some cases, shifting the target from unhealthy tissues to the whole organ can represent an advantage. Specifically, the natural organ-specific retention of nanotherapeutics following intravenous administration as seen in the lung, liver, and spleen can be strategically exploited to enhance drug delivery. Herein, we outline the development of a cell-based delivery system using macrophages as a delivery vehicle. When loaded with a chemotherapeutic payload (i.e., doxorubicin), these cellular vectors (CELVEC) were shown to provide continued release within the lung. This study provides proof-of-concept evidence of an alternative class of biomimetic delivery vectors that capitalize on cell size to provide therapeutic advantages for pulmonary treatments.
AB - Despite recent advances in drug delivery, the targeted treatment of unhealthy cells or tissues continues to remain a priority. In cancer (much like other pathologies), delivery vectors are designed to exploit physical and biological features of unhealthy tissues that are not always homogenous across the disease. In some cases, shifting the target from unhealthy tissues to the whole organ can represent an advantage. Specifically, the natural organ-specific retention of nanotherapeutics following intravenous administration as seen in the lung, liver, and spleen can be strategically exploited to enhance drug delivery. Herein, we outline the development of a cell-based delivery system using macrophages as a delivery vehicle. When loaded with a chemotherapeutic payload (i.e., doxorubicin), these cellular vectors (CELVEC) were shown to provide continued release within the lung. This study provides proof-of-concept evidence of an alternative class of biomimetic delivery vectors that capitalize on cell size to provide therapeutic advantages for pulmonary treatments.
UR - http://www.scopus.com/inward/record.url?scp=85077786313&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077786313&partnerID=8YFLogxK
U2 - 10.1038/s41598-019-55909-x
DO - 10.1038/s41598-019-55909-x
M3 - Article
C2 - 31932600
AN - SCOPUS:85077786313
VL - 10
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 172
ER -